nach oben

Erschienen in:

01.07.2011 | Article

Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4

verfasst von: M. N. Pham, M. I. Hawa, C. Pfleger, M. Roden, G. Schernthaner, P. Pozzilli, R. Buzzetti, W. Scherbaum, J. Seissler, H. Kolb, S. Hunter, R. D. G. Leslie, N. C. Schloot, Action LADA Study Group

Erschienen in: Diabetologia | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Systemic pro- and anti-inflammatory cytokines are associated with both type 1 and type 2 diabetes, while their role in latent autoimmune diabetes in adults (LADA) is unclear. Therefore, we compared cytokine concentrations in patients with LADA, type 1 or type 2 diabetes and healthy individuals to test the hypothesis that differences of cytokine concentrations between all groups are attributable to diabetes type and BMI.

Methods

The pro-inflammatory cytokines IL-6 and TNF-α, and the anti-inflammatory cytokines IL-1 receptor antagonist (IL-1RA) and IL-10 were measured in 90 participants with type 1 diabetes, 61 with LADA, 465 with type 2 diabetes and 41 control participants using multiple regression models adjusted for BMI, sex, age, blood pressure and diabetes duration.

Results

Patients with type 2 diabetes had higher concentrations of systemic IL-1RA, IL-6 and TNF-α cytokines than patients with either LADA or type 1 diabetes (p < 0.0001 for all differences). Cytokine concentrations in controls were lower than those in all diabetes types (p < 0.04). Increased BMI was positively associated with higher systemic cytokine concentrations in all diabetes types (p < 0.0001). Despite the association of cytokines with anthropometric data, differences between diabetes forms persisted also after adjusting analysis for the confounders BMI, age, sex, disease duration and blood pressure (p < 0.04).

Conclusions/interpretation

Although body mass associates positively with pro- and anti-inflammatory cytokine levels, patients with type 2 diabetes have higher cytokine levels independent of the prevailing BMI. LADA and type 1 diabetes could not be distinguished by systemic cytokines.

Butler AE, Janson J, Bonner-Weir, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110PubMedCrossRef

Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444:860–867PubMedCrossRef

Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116:1973–1801

Pickup JC, Crook MA (1998) Is type 2 diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241–1248PubMedCrossRef

Pickup JC, Mattock MB, Chusney GD, Burt D (1997) NIDDM as a disease of the immune system: association of acute phase reactants and interleukin-6 with metabolic syndrome. Diabetologia 40:1286–1292PubMedCrossRef

Kolb H, Mandrup-Poulsen T (2005) An immune origin of type 2 diabetes? Diabetologia 48:1038–1050PubMedCrossRef

Herder C, Brunner EJ, Rathmann W et al (2009) Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care 32:421–423PubMedCrossRef

Carstensen M, Herder C, Kivimäki M et al (2010) Accelerated increase in serum interleukin-1 receptor antagonist (IL-1Ra) starts 6 years before diagnosis of type 2 diabetes: whitehall II prospective cohort study. Diabetes 59:1222–1227PubMedCrossRef

Herder C, Zierer A, Koenig W, Roden M, Meisinger C, Thorand B (2009) Transforming growth factor-beta 1 and incident type 2 diabetes: results from the MONICA/KORA case cohort study, 1984–2002. Diabetes Care 32:1921–1923PubMedCrossRef

10.

He L, He M, Lv X, Pu D, Su P, Liu Z (2010) NF-kappaB binding activity and pro-inflammatory cytokines expression correlate with body mass index but not glycosylated haemoglobin in Chinese population. Diab Res Clin Pract 90:73–80CrossRef

11.

Ventre J, Doebber T, Wu M et al (1997) Targeted disruption of the tumor necrosis factor-alpha gene: metabolic consequences in obese and nonobese mice. Diabetes 46:1526–1531PubMedCrossRef

12.

Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95:2409–2415PubMedCrossRef

13.

Ziccardi P, Nappo F, Giugliano G et al (2002) Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105:804–809PubMedCrossRef

14.

Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE (2001) Circulating interleukin-6 relation to adiposity, insulin action, and insulin secretion. Obes Res 97:414–417CrossRef

15.

Juge-Aubry CE, Somm E, Pernin A et al (2005) Adipose tissue is a regulated source of interleukin-10. Cytokine 29:270–274PubMed

16.

Juge-Aubry CE, Somm E, Giusti V et al (2003) Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 52:1104–1110PubMedCrossRef

17.

Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517–1526PubMedCrossRef

18.

Atkinson MA, Eisenbarth GS (2001) Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358:221–229PubMedCrossRef

19.

Tisch R, McDevitt H (1996) Insulin-dependent diabetes mellitus. Cell 85:291–297PubMedCrossRef

20.

Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S, Eizirik DL (2005) Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54(suppl2):S97–S107PubMedCrossRef

21.

Eizirik DL, Colli ML, Ortis F (2009) The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 5:219–226PubMedCrossRef

22.

Mandrup-Poulsen T (1990) Cytokine and free radicals as effector molecules in the destruction of pancreatic beta cells. Curr Top Microbiol Immunol 164:169–193PubMed

23.

Campbell IL, Oxbrow L, Harrison LC (1991) Reduction in Insulitis following administration of IFN-gamma and TNF-alpha in the NOD mouse. J Autoimm 4:249–262CrossRef

24.

Nicoletti F, Zaccone P, Di Marco R et al (1998) Paradoxical antidiabetogenic effect of gamma-interferon in DP-BB rats. Diabetes 47:32–38PubMedCrossRef

25.

Ortis F, Naamane N, Flamez D et al (2010) Cytokines interleukin-1β and tumor necrosis factor-α regulate different transcriptional and alternative splicing networks in primary β-cells. Diabetes 59:358–374PubMedCrossRef

26.

Hoorens A, Stangé G, Pavlovic D, Pipeleers D (2001) Distinction between interleukin-1-induced necrosis and apoptosis of islet cells. Diabetes 50:551–557PubMedCrossRef

27.

Pfleger C, Meierhoff G, Kolb H, Schloot NC, p520/521 Study Group (2010) Association of T cell reactivity with beta-cell function in recent onset type 1 diabetes patients. J Autoimmun 34:127–135PubMedCrossRef

28.

Pfleger C, Kaas A, Hansen L et al (2008) Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes. Clin Immunol 128:57–65PubMedCrossRef

29.

Pfleger C, Mortensen HB, Hansen L et al (2008) Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes. Diabetes 57:929–937PubMedCrossRef

30.

Leslie RD, Kolb H, Schloot NC et al (2008) Diabetes classification: grey zones, sound and smoke: Action LADA 1. Diab Metab Res Rev 24:511–519CrossRef

31.

Hosszúfalusi N, Vatay A, Rajczy K et al (2003) Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 26:452–457PubMedCrossRef

32.

Gottsäter A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G (1993) Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis in type 2 diabetic patients. Diabetes Care 16:902–910PubMedCrossRef

33.

Hawa MI, Thivolet C, Mauricio D et al (2009) Metabolic syndrome and autoimmune diabetes: Action LADA 3. Diabetes Care 32:160–164PubMedCrossRef

34.

Meier CA, Bobbioni E, Gabay C, Assimacopoulos-Jeannet F, Golay A, Dayer JM (2002) IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin. J Clin Endocrinol Metab 87:1184–1188PubMedCrossRef

35.

Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T (1998) Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 83:2907–2910PubMedCrossRef

36.

Shoelson SE, Herrero L, Naaz A (2007) Obesity, inflammation, and insulin resistance. Gastroenterology 132:2169–2180PubMedCrossRef

37.

Shoelson SE, Goldfine AB (2009) Getting away from glucose: fanning the flames of obesity-induced inflammation. Nat Med 15:373–374PubMedCrossRef

38.

Rolandsson O, Palmer JP (2010) Latent autoimmune diabetes in adults (LADA) is dead: long live autoimmune diabetes. Diabetologia 53:1250–1253PubMedCrossRef

39.

Pradhan AD, Manson JAE, Rifai N, Buring JE, Ridker (2001) C-reactive Protein, Interleukin-6, and risk of developing type 2 diabetes mellitus. JAMA 286:327–334PubMedCrossRef

40.

Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I (2006) Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 55:774–779PubMedCrossRef

41.

Basu S, Larsson A, Vessby J, Vessby B, Berne C (2005) Type 1 diabetes is associated with increased cyclooxygenase and cytokine-mediated inflammation. Diab Care 28:1371–1375CrossRef

42.

Trøseid M, Seljeflot I, Hjerkinn EM, Arnesen H (2009) Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: synergistic effect of inflammation and hyperglycemia. Diabetes Care 32:486–492PubMedCrossRef

43.

Hartkamp A, Geenen R, Bijl M, Kruize AA, Godaert GL, Derksen RH (2004) Serum cytokine levels related to multiple dimensions of fatigue in patients with primary Sjogren’s syndrome. Ann Rheum Dis 63:1335–1337PubMedCrossRef

44.

Mysliwiec M, Zorena K, Balcerska A, Mysliwska J, Lipowski P, Raczynska K (2006) The activity of N-acetyl-beta-D-glucosaminidase and tumour necrosis factor-alpha at early stage of diabetic retinopathy development in type 1 diabetes mellitus children. Clin Biochem 39:851–856PubMedCrossRef

45.

Weihrauch MR, Manzke O, Beyer M et al (2005) Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin’s disease potential for a prognostic factor. Cancer Res 65:5516–5519PubMedCrossRef

Titel: Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4
verfasst von: M. N. Pham
M. I. Hawa
C. Pfleger
M. Roden
G. Schernthaner
P. Pozzilli
R. Buzzetti
W. Scherbaum
J. Seissler
H. Kolb
S. Hunter
R. D. G. Leslie
N. C. Schloot
Action LADA Study Group
Publikationsdatum: 01.07.2011
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 7/2011
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-011-2088-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4